Aligos Therapeutics, developing several different hep B and NASH treatments, files for $100M IPO raise
Another biotech filed to go public late Friday as the 2020 IPO party rages on.
Aligos Therapeutics, focusing on chronic hepatitis B and NASH …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.